Colchicine Oral Uses, Side Effects, Interactions, Pictures, Warnings

3.7.2018 author Kevin Bargeman

This medication is used to prevent or treat gout attacks (flares). Colchicine works by decreasing swelling and lessening the build up of uric acid crystals that cause pain in the affected joint(s). This medication is also used to prevent attacks of pain in the abdomen, chest, or.

Inflammation of the Covering of the Heart or Pericardium.

Do not share this medication with others.

Does Colchicine interact with other medications?

The recommended dose is 1.2 milligrams at the first sign of an attack, followed by 0.6 milligrams one hour later. Ask your doctor ahead of time about how soon you can repeat treatment with this medication if you have another gout attack. The maximum recommended dose is 1.8 milligrams taken over a 1-hour period. This medication works best if you take it at the first sign of an attack.

Colchicine (Colchicine) Side Effects, Interactions, Warning, Dosage

10.14.2018 author Zachary Arnold

Colchicine consists of pale yellow scales or powder; it darkens on exposure to light. Colchicine is soluble in water, freely soluble in alcohol, and slightly soluble.

There is no difference between men and women in the pharmacokinetic disposition of colchicine.

Colchicine is not effectively removed by hemodialysis. Colchicine is known to be excreted in urine in humans and the presence of severe renal impairment has been associated with colchicine toxicity. Dose reduction or alternatives should be considered for the prophylaxis of gout flares in patients with severe renal impairment. No dedicated pharmacokinetic study has been conducted using colchicine capsules in patients with varying degrees of renal impairment.

Colchicine Side Effects, Dosage, Uses & More

9.13.2018 author Jonathan

Colchicine is an oral drug used to treat or prevent gout symptoms, or to treat familial Mediterranean fever. Learn about side effects, warnings, and more.

This can help make sure you stay safe while you take this drug. Your doctor may do blood tests to check your:. Your doctor may also check for side effects.

For people with liver disease: Your liver processes this drug in your body. To help avoid this, your doctor may lower your dose of colchicine. If it’s not working well, levels of this drug may build up in your body, raising your risk of side effects.

The kidneys of older adults may not work as well as they used to. This raises your risk of side effects.


8.12.2018 author Zachary Arnold

Colchicine (as Colcrys or Mitigare) is a medication most commonly used to treat gout. In addition to gout, colchicine is used to treat familial Mediterranean fever.

[15]. Colchicine is used widely in the treatment of familial Mediterranean fever, [12] in which it reduces attacks and the long-term risk of amyloidosis.

state Medicaid programs from $1 million to $50 million. URL Pharma also received seven years of market exclusivity for Colcrys in treatment of familial Mediterranean fever, under the Orphan Drug Law. Medicare also paid significantly higher costs—making this a direct money-loser for the government. (In a similar case, thalidomide was approved in 1998 as an orphan drug for leprosy and in 2006 for multiple myeloma.

Colchicine in the cardiology clinic No longer just for gout

7.11.2018 author Jonathan

Historical use of colchicine, or its precursors, dates back several thousand years, with reports appearing in records from ancient Egyptians, Greeks and Arabic.

These clinical trials were conducted by the same research team in Italy and evaluated colchicine dosed in increments of 0.5 mg. Finally, doses were halved in patients weighing less than 70 kg or who were intolerant to full doses. However, in the United States, the only available dosage form is a 0.6-mg tablet; therefore, treatment regimens have to be extrapolated from trials using the currently available tablet strength (eg, 1.2 mg twice daily on day 1, followed by maintenance 0.6 mg twice daily).

Colchicine reduced incidence of post-cardiac surgery AF from 22% to 12% at 1 month and early recurrent AF after ablation with pulmonary vein isolation from 34% to 16% after 3 months.